Protein S K196E mutation, a genetic risk factor for venous thromboembolism, is limited to Japanese

2013 ◽  
Vol 132 (2) ◽  
pp. 314-315 ◽  
Author(s):  
Wanyang Liu ◽  
Tong Yin ◽  
Hiroko Okuda ◽  
Kouji H. Harada ◽  
Yang Li ◽  
...  
PLoS ONE ◽  
2015 ◽  
Vol 10 (7) ◽  
pp. e0133196 ◽  
Author(s):  
Keiko Maruyama ◽  
Masashi Akiyama ◽  
Koichi Kokame ◽  
Akiko Sekiya ◽  
Eriko Morishita ◽  
...  

Blood ◽  
2006 ◽  
Vol 107 (4) ◽  
pp. 1737-1738 ◽  
Author(s):  
Rina Kimura ◽  
Shigenori Honda ◽  
Tomio Kawasaki ◽  
Hajime Tsuji ◽  
Seiji Madoiwa ◽  
...  

1998 ◽  
Vol 80 (09) ◽  
pp. 366-369 ◽  
Author(s):  
Inma Coll ◽  
Dolors Llobet ◽  
Elisabeth del Río ◽  
Arturo Oliver ◽  
José Mateo ◽  
...  

SummaryWe investigated the prevalence of the new recently reported mutation in the prothrombin gene (20210 A) in a sample of 116 unrelated patients with venous thromboembolism. We found 20 heterozygous carriers (17.2%, CI 95% 10.4-21.1). In comparison, we observed 13 carriers among 201 healthy unmatched controls (6.5%, CI 3.5-10.8). The 20210 A mutation seems to increase the risk of venous thrombosis 3-fold (odds ratio 3.1, 95% CI 1.4-6.6). Considering only patients with a first event (n = 62) the OR was 2.0 (p = 0.18, NS) while those with recurrent events (n = 54) showed an OR of 5.9 (95% CI 2.5-14.4). A majority of heterozygous patients (55%) presented a second thrombophilic factor and 60% of affected females had their first event before 30 years of age, while on oral contraceptive treatment. The prevalence found in this study for healthy people is the highest reported to date. The 20210 A variant appears to be the most prevalent genetic risk factor among patients with thrombosis in our geographical area.


Blood ◽  
1995 ◽  
Vol 85 (12) ◽  
pp. 3518-3523 ◽  
Author(s):  
B Zoller ◽  
A Berntsdotter ◽  
P Garcia de Frutos ◽  
B Dahlback

Inherited resistance to activated protein C (APC), which is caused by a single point mutation in the gene for factor V, is a common risk factor for thrombosis. In this study, the prevalence of APC resistance in 18 unrelated thrombosis-prone families with inherited protein S deficiency was investigated to determine its role as additional genetic risk factor for thrombosis. In addition, a detailed evaluation of the clinical manifestations in these families was performed. Venous thrombotic events had occurred in 47% of the protein S-deficient patients (64/136) and in 7% of relatives without protein S deficiency (14/191). As estimated from Kaplan-Meier analysis, 50% of protein S-deficient family members and 12% of those without protein S deficiency had had manifestation of venous thromboembolism at the age of 45 years. The age at the first thrombotic event ranged from 10 to 81 years (mean, 32.5 years) and a large intrafamilial and interfamilial variability in expression of thrombotic symptoms was seen. The factor V gene mutation related to APC resistance was present in 6 (38%) of 16 probands available for testing; in total, the mutation was found in 7 (39%) of the 18 families. In family members with combined defects, 72% (13/18) had had thrombosis as compared with 19% (4/21) of those with only protein S deficiency and 19% (4/21) of those with only the factor V mutation. In conclusion, APC resistance was found to be highly prevalent in thrombosis-prone families with protein S deficiency and was an additional genetic risk factor for thrombosis in these families. The results suggest thrombosis-prone families with protein S deficiency often to be affected by yet another genetic defect.


1998 ◽  
Vol 80 (09) ◽  
pp. 372-375 ◽  
Author(s):  
Hidemi Yoshida ◽  
Tadaatsu Imaizumi ◽  
Koji Fujimoto ◽  
Hiroyuki Itaya ◽  
Makoto Hiramoto ◽  
...  

SummaryPlatelet-activating factor (PAF) acetylhydrolase is an enzyme that inactivates PAF. Deficiency of this enzyme is caused by a missense mutation in the gene. We previously found a higher prevalence of this mutation in patients with ischemic stroke. This fact suggests that the mutation might enhance the risk for stroke through its association with hypertension. We have addressed this hypothesis by analyzing the prevalence of the mutation in hypertension. We studied 138 patients with essential hypertension, 99 patients with brain hemorrhage, and 270 healthy controls. Genomic DNA was analyzed for the mutant allele by the polymerase-chain reaction. The prevalence of the mutation was 29.3% (27.4% heterozygotes and 1.9% homozygotes) in controls and 36.2% in hypertensives and the difference was not significant. The prevalence in patients with brain hemorrhage was significantly higher than the control: 32.6% heterozygotes and 6.1% homozygotes (p <0.05). PAF acetylhydrolase deficiency may be a genetic risk factor for vascular diseases.


Sign in / Sign up

Export Citation Format

Share Document